SPK Acquisition Corp (SPK) Financial Statements (2026 and earlier)
Company Profile
| Business Address |
ROOM 368, 302 BUWEI SHANGHAI, 200131 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)Annual | Quarterly
| 9/30/2022 Q3 | 6/30/2022 Q2 | 3/31/2022 Q1 | 12/31/2021 Q4 | 9/30/2021 Q3 | 6/30/2021 Q2 | 3/31/2021 Q1 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 51,480,930 | 50,912,228 | 51,172,745 | 51,200,452 | 50,000,000 | 137,485 | |||
| Cash and cash equivalent | 52,269 | 259,228 | 287,933 | 137,485 | |||||
| Short-term investments | 51,428,661 | 50,912,228 | 50,913,517 | 50,912,519 | 50,000,000 | ||||
| Prepaid expense | 201,957 | ||||||||
| Deferred costs | 127,994 | ||||||||
| Other undisclosed current assets | 67,500 | 162,673 | 108,198 | ||||||
| Total current assets: | 51,548,430 | 51,074,901 | 51,280,943 | 51,200,452 | 50,201,957 | 265,479 | |||
| Noncurrent Assets | |||||||||
| Other undisclosed assets | 159,457 | 557,128 | |||||||
| TOTAL ASSETS: | 51,548,430 | 51,074,901 | 51,280,943 | 51,359,909 | 50,759,085 | 265,479 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities, including: | 454,023 | 353,619 | 103,175 | 115,299 | 2,455 | 2,190 | |||
| Accounts payable | 454,023 | 353,619 | 103,175 | 115,299 | |||||
| Other undisclosed accounts payable and accrued liabilities | 2,455 | 2,190 | |||||||
| Debt | |||||||||
| Due to related parties | 8,366 | 2,883 | |||||||
| Other undisclosed current liabilities | 1,542,958 | 1,535,158 | 1,548,158 | 240,494 | |||||
| Total current liabilities: | 2,005,347 | 1,888,777 | 1,654,216 | 115,299 | 2,455 | 242,684 | |||
| Noncurrent Liabilities | |||||||||
| Other undisclosed liabilities | 1,542,758 | 1,632,700 | |||||||
| Total liabilities: | 2,005,347 | 1,888,777 | 1,654,216 | 1,658,057 | 1,635,155 | 242,684 | |||
| Temporary equity, including noncontrolling interest | 135,952 | 135,952 | 135,952 | ||||||
| Equity | |||||||||
| Equity, attributable to parent, including: | 1,884,022 | (1,725,836) | (1,285,233) | (1,210,667) | (876,070) | 22,795 | |||
| Common stock | 151 | 151 | 151 | 151 | 167 | 144 | |||
| Additional paid in capital | 24 | ||||||||
| Retained earnings (accumulated deficit) | 1,884,173 | (1,725,987) | (1,285,384) | (1,210,818) | (876,237) | (2,205) | |||
| Other undisclosed equity, attributable to parent | (302) | 24,832 | |||||||
| Other undisclosed equity | 50,776,008 | 50,776,008 | 50,912,519 | 50,000,000 | |||||
| Total equity: | 1,884,022 | 49,050,172 | 49,490,775 | 49,701,852 | 49,123,930 | 22,795 | |||
| Other undisclosed liabilities and equity | 47,523,109 | ||||||||
| TOTAL LIABILITIES AND EQUITY: | 51,548,430 | 51,074,901 | 51,280,943 | 51,359,909 | 50,759,085 | 265,479 | |||
Income Statement (P&L) (USD)Annual | Quarterly
| 9/30/2022 Q3 | 6/30/2022 Q2 | 3/31/2022 Q1 | 12/31/2021 Q4 | 9/30/2021 Q3 | 6/30/2021 Q2 | 3/31/2021 Q1 | ||
|---|---|---|---|---|---|---|---|---|
| Other undisclosed income before gain (loss) on sale of properties | ✕ | ✕ | ✕ | 346,628 | ✕ | ✕ | ✕ | |
| Revenues | 1,018,951 | 998 | 558 | |||||
| Underwriting income | ✕ | ✕ | 1,018,240 | |||||
| Other operating income | 558 | |||||||
| Gross profit: | 1,018,951 | 998 | 558 | |||||
| Operating expenses | (190,107) | (441,314) | (76,122) | (307,239) | (37,184) | (2,205) | ||
| Other undisclosed operating income (loss) | (1,556) | 4,410 | ||||||
| Operating income (loss): | (190,107) | 577,637 | (76,680) | (306,681) | (37,184) | 2,205 | ||
| Nonoperating income (Other Nonoperating income) | 37,945 | 711 | ||||||
| Other undisclosed income from continuing operations before equity method investments, income taxes | 1,556 | |||||||
| Income (loss) from continuing operations before income taxes: | (152,162) | 578,348 | (75,124) | (306,681) | (37,184) | 2,205 | ||
| Income tax benefit | ||||||||
| Income (loss) from continuing operations: | (152,162) | 578,348 | (75,124) | (306,681) | (37,184) | 2,205 | ||
| Income (loss) before gain (loss) on sale of properties: | (342,269) | 137,034 | 271,504 | (613,920) | (37,184) | 2,205 | ||
| Loss from discontinued operations | (190,107) | (441,314) | (307,239) | |||||
| Other undisclosed net income (loss) | 190,107 | (577,637) | (346,628) | 307,239 | ||||
| Net income (loss): | (152,162) | (440,603) | (75,124) | (306,681) | (37,184) | 2,205 | ||
| Other undisclosed net loss attributable to parent | (4,410) | |||||||
| Net loss attributable to parent: | (152,162) | (440,603) | (75,124) | (306,681) | (37,184) | (2,205) | ||
| Other undisclosed net income available to common stockholders, basic | 881,206 | 842,388 | ||||||
| Net income (loss) available to common stockholders, basic: | (152,162) | 440,603 | 767,264 | (306,681) | (37,184) | (2,205) | ||
| Other undisclosed net loss available to common stockholders, diluted | (881,206) | (842,388) | ||||||
| Net loss available to common stockholders, diluted: | (152,162) | (440,603) | (75,124) | (306,681) | (37,184) | (2,205) | ||
Comprehensive Income (USD)Annual | Quarterly
| 9/30/2022 Q3 | 6/30/2022 Q2 | 3/31/2022 Q1 | 12/31/2021 Q4 | 9/30/2021 Q3 | 6/30/2021 Q2 | 3/31/2021 Q1 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | (152,162) | (440,603) | (75,124) | (306,681) | (37,184) | 2,205 | ||
| Comprehensive income (loss), net of tax, attributable to parent: | (152,162) | (440,603) | (75,124) | (306,681) | (37,184) | 2,205 | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.